Cargando…

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults

BACKGROUND AND OBJECTIVE: Voriconazole is an important broad-spectrum anti-fungal drug with nonlinear pharmacokinetics. The aim of this single centre fixed-sequence open-label drug–drug interaction trial in healthy participants (N = 17) was to determine whether microdosed probe drugs for CYP3A and C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muhareb, Amin, Blank, Antje, Meid, Andreas D., Foerster, Kathrin I., Stoll, Felicitas, Burhenne, Jürgen, Haefeli, Walter E., Mikus, Gerd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450012/ https://www.ncbi.nlm.nih.gov/pubmed/37505445 http://dx.doi.org/10.1007/s40262-023-01287-7

Ejemplares similares

Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans
por: Elbe, Annika, et al.
Publicado: (2022)

Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail
por: Rohr, Brit Silja, et al.
Publicado: (2021)

Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion
por: Nassar, Yomna M., et al.
Publicado: (2022)

Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial
por: Stoll, Felicitas, et al.
Publicado: (2020)

Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug–drug interactions with different perpetrator drugs
por: Mikus, Gerd, et al.
Publicado: (2020)

Oral bioavailability of microdoses and therapeutic doses of midazolam as a 2-dimensionally printed orodispersible film in healthy volunteers
por: Breithaupt, Mareile H., et al.
Publicado: (2022)

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat
por: Hohmann, Nicolas, et al.
Publicado: (2020)

Frailty as a Marker for the Plasma Concentrations of Direct Oral Anticoagulants in Older Patients: Results of an Exploratory Study
por: Eidam, Annette, et al.
Publicado: (2023)

Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
por: Wiebe, Sabrina T., et al.
Publicado: (2020)

Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial
por: Vay, Manuela, et al.
Publicado: (2020)

Intact plasma quantification of the large therapeutic lipopeptide bulevirtide
por: Sauter, Max, et al.
Publicado: (2021)

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
por: Shi, Hui-Yan, et al.
Publicado: (2010)

Drug–drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer
por: Park, Gab-jin, et al.
Publicado: (2017)

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children
por: Brussee, Janneke M., et al.
Publicado: (2019)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N-oxide
por: Schulz, Josefine, et al.
Publicado: (2022)

Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients
por: Ebrahimpour, Sholeh, et al.
Publicado: (2017)

Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in children
por: Chen, Xiaomin, et al.
Publicado: (2022)

Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections
por: Chuwongwattana, Sumonrat, et al.
Publicado: (2020)

Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients
por: Li, Zi-Wei, et al.
Publicado: (2017)

CYP51A1 polymorphism and voriconazole-associated hepatotoxicity in children undergoing hematopoietic cell transplant
por: Takahashi, Takuto, et al.
Publicado: (2021)

Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients
por: Hu, Lin, et al.
Publicado: (2023)

2566. Effect of CYP2C19 on Voriconazole Pharmacokinetics in Children with Malignancy or Inborn Errors in Immunity
por: Shoji, Kensuke, et al.
Publicado: (2023)

Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data
por: Kluwe, Franziska, et al.
Publicado: (2023)

Drug–Drug Interactions with Direct Oral Anticoagulants
por: Foerster, Kathrin I., et al.
Publicado: (2020)

Correction to: Drug–Drug Interactions with Direct Oral Anticoagulants
por: Foerster, Kathrin I., et al.
Publicado: (2020)

CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers
por: Zhu, Vanessa, et al.
Publicado: (2023)

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
por: Chung, Hyewon, et al.
Publicado: (2015)

Cold-Induced Lipoprotein Clearance in Cyp7b1-Deficient Mice
por: Evangelakos, Ioannis, et al.
Publicado: (2022)

Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism
por: Schulz, Josefine, et al.
Publicado: (2022)

Quantification of CYP3A and Drug Transporters Activity in Healthy Young, Healthy Elderly and Chronic Kidney Disease Elderly Patients by a Microdose Cocktail Approach
por: Rattanacheeworn, Punyabhorn, et al.
Publicado: (2021)

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP
por: Ou, Ying C., et al.
Publicado: (2021)

Genetic Variation in Plant CYP51s Confers Resistance against Voriconazole, a Novel Inhibitor of Brassinosteroid-Dependent Sterol Biosynthesis
por: Rozhon, Wilfried, et al.
Publicado: (2013)

Evaluation of mRNA Expression Levels of cyp51A and mdr1, Candidate Genes for Voriconazole Resistance in Aspergillus flavus
por: Fattahi, Azam, et al.
Publicado: (2015)

A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis
por: Kim, Yun, et al.
Publicado: (2019)

Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
por: Zhong, Xuefeng, et al.
Publicado: (2018)

A 23 bp cyp51A Promoter Deletion Associated With Voriconazole Resistance in Clinical and Environmental Isolates of Neocosmospora keratoplastica
por: James, Jasper Elvin, et al.
Publicado: (2020)

Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
por: Mafuru, Magesa, et al.
Publicado: (2021)

Application of Population Pharmacokinetic Analysis to Characterize CYP2C19 Mediated Metabolic Mechanism of Voriconazole and Support Dose Optimization
por: Li, SiChan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_116u432taveitmtr325ot608s4